Potential Effect Of Green Tea Extract For Adjuvant Treatment Of Acute Ischemic Stroke by S100ß Upregulation In Non Thrombolysis Patient

Abstract

Abstract Purpose To determine the efficacy of green tea extract for adjuvant treatment of acute ischemic stroke in non-thrombolysis patients. Methods A double-blind, randomized controlled trial was conducted in January-November 2021. The subjects were all acute ischemic stroke patients who presented to the ER during recruitment. Patients were then randomized into control or intervention groups and followed up to 30 days of treatment. On days 0,7,14, and 30 of the treatment, NIHSS, mRS and MoCAIna scores were measured. IL-10 and S100ß were measured on the first and seventh days of admission. Results All the delta-NIHSS (day 7 − 0, day 14 − 0, day 30 − 0) were found to be statistically significant in the intervention group (p = 0.019, p = 0.002 and p < 0.001, respectively), especially the NIHSS improvement on day 30 − 0 (RR 4,333 (1,162–16,157); CI 95%; p = 0.014). On day 30, the mRS score was significantly higher in the intervention group compared to the control group (1.00 (0.00–4.00) vs 2.00 (1.00–4.00); p = 0.046). The delta-mRS day 14 − 0 and 30 − 0 were statistically significant for the intervention group (p = 0.042 and p = 0.001). There is no significant difference between the two groups in the MoCAIna score and IL-10 level. On days 0 and 7, the S100ß were found to be statistically significant in the intervention group (p = 0.041 and p = 0.013). The delta- S100β day 7 − 0 was found to be significantly lower in the intervention groups compared to the control group (-1.388 (-4.420–5.010) 0.900 (-1.800–5.660); p-value < 0.001). Conclusions The green tea extract with EGCG through up-regulation S100ß can improve the clinical outcomes of acute cerebral infarction patients.